Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer

References

• FerlayJShinHRBrayFFormanDMathersCParkinDMEstimates of worldwide burden of cancer in 2008: GLOBOCAN 2008Int J Cancer2010127122893291721351269
   PubMed Web of Science ®Google Scholar
• World Health OrganizationInternational Agency for Research on Cancer. World Cancer ReportLyon, FranceIARC Press2008
   Google Scholar
• ScagliottiGVParikhPvon PawelJPhase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancerJ Clin Oncol200826213543355118506025
   PubMed Web of Science ®Google Scholar
• MaemondoMInoueAKobayashiKGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med2010362252380238820573926
   PubMed Web of Science ®Google Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
   PubMed Web of Science ®Google Scholar
• ShepherdFARodrigues PereiraJCiuleanuTErlotinib in previously treated non-small-cell lung cancerN Engl J Med2005353212313216014882
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol201112873574221783417
   PubMed Web of Science ®Google Scholar
• YangJC-HSchulerMHYamamotoNLUX-Lung 3: a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutationsASCO Meeting Abstracts201230Suppl 15LBA7500
   Google Scholar
• KwakELBangY-JCamidgeDRAnaplastic lymphoma kinase inhibition in non-small-cell lung cancerN Engl J Med2010363181693170320979469
   PubMed Web of Science ®Google Scholar
• GarassinoMCMartelliOBettiniATAILOR: Phase III trial comparing erlotinib with docetaxel in the second-line treatment of patients with NSCLC with wild-type (wt) EGFRASCO Meeting Abstracts201230Suppl 15LBA7501
   Google Scholar
• ChoiYLSodaMYamashitaYEML4-ALK mutations in lung cancer that confer resistance to ALK inhibitorsN Engl J Med2010363181734173920979473
   PubMed Web of Science ®Google Scholar
• KobayashiSBoggonTJDayaramTEGFR mutation and resistance of non-small-cell lung cancer to gefitinibN Engl J Med2005352878679215728811
   PubMed Web of Science ®Google Scholar
• PaoWMillerVAPolitiKAAcquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainPLoS Med200523e7315737014
   PubMed Web of Science ®Google Scholar
• SasakiTKoivunenJOginoAA novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitorsCancer Res201171186051606021791641
   PubMed Web of Science ®Google Scholar
• BeanJBrennanCShihJYMET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProc Natl Acad Sci U S A200710452209322093718093943
   PubMed Web of Science ®Google Scholar
• EngelmanJAZejnullahuKMitsudomiTMET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingScience200731658271039104317463250
   PubMed Web of Science ®Google Scholar
• KrisMGJohnsonBEKwiatkowskiDJIdentification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI’s Lung Cancer Mutation Consortium (LCMC)ASCO Meeting Abstracts201129Suppl 18CRA7506
   Google Scholar
• TrusolinoLBertottiAComoglioPMMET signalling: principles and functions in development, organ regeneration and cancerNat Rev Mol Cell Biol2010111283484821102609
   PubMed Web of Science ®Google Scholar
• MaPCTretiakovaMSMacKinnonACExpression and mutational analysis of MET in human solid cancersGenes Chromosomes Cancer200847121025103718709663
   PubMed Web of Science ®Google Scholar
• MaPCJagadeeswaranRJagadeeshSFunctional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancerCancer Res20056541479148815735036
   PubMed Web of Science ®Google Scholar
• MunshiNJeaySLiYARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activityMol Cancer Ther2010961544155320484018
   PubMed Web of Science ®Google Scholar
• StellaGMBenvenutiSComoglioPMTargeting the MET oncogene in cancer and metastasesExpert Opin Investig Drugs2010191113811394
   PubMed Web of Science ®Google Scholar
• JinHYangRZhengZMetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survivalCancer Res200868114360436818519697
   PubMed Web of Science ®Google Scholar
• EathirajSPalmaRVolckovaEDiscovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197J Biol Chem201128623206662067621454604
   PubMed Web of Science ®Google Scholar
• MaoCQiuL-XLiaoR-YKRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studiesLung Cancer201069327227820022659
   PubMed Web of Science ®Google Scholar
• MarabeseMRulliEBettiniAKRAS mutational status impact progression-free survival of patients treated with platinum-based chemotherapy in NSCLCMol Cancer Ther201110 Suppl 1B77
   Google Scholar
• MetroGChiariRDurantiSImpact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotypeLung Cancer2012781818622770374
   PubMed Web of Science ®Google Scholar
• PrevidiSAbbadessaGDaloFFranceDSBrogginiMBreast cancer-derived bone metastasis can be effectively reduced through specific c-Met inhibitor tivantinib (ARQ 197) and shRNA c-Met knockdownMol Cancer Ther201211121422322027690
   PubMed Web of Science ®Google Scholar
• SavageRZhongCHallTIn vitro ADME properties of ARQ-197. Comparison to in vivo dataPoster 1291 presented at the 99th American Association for Cancer Research Annual MeetingPhiladelphia, PAApril 12–16, 2009
   Google Scholar
• YapTAOlmosDBrunettoATPhase I trial of a selective c-Met inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studiesJ Clin Oncol201129101271127921383285
   PubMed Web of Science ®Google Scholar
• YamamotoNNishinaTSugioKTwo patients with NSCLC achieved PR by ARQ 197 monotherapy. Final results of the first Asian phase I trial of selective c-Met inhibitor ARQ 197J Thorac Oncol201166S1170
   Web of Science ®Google Scholar
• CamachoLHBendellJCPantSPhase 1B results of c-Met inhibitor tivantinib (ARQ 197) in combination with gemcitabine (GEM) in a cohort of patients (PTS) with advanced thoracic tumorsJ Thorac Oncol201166S1265
   Web of Science ®Google Scholar
• GoldmanJWLauxIChaiFPhase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinibCancer2012118235903591122605616
   PubMed Web of Science ®Google Scholar
• SequistLVVon PawelJGarmeyEGRandomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancerJ Clin Oncol201129243307331521768463
   PubMed Web of Science ®Google Scholar
• RodigSJSequistLSchillerJHAn exploratory biomarker analysis evaluating the effect of the c-Met inhibitor tivantinib (ARQ 197) and erlotinib in patients with NSCLC in a randomized, double-blinded phase 2 studyPaper presented at the 102nd Annual Meeting of the American Association for Cancer ResearchChicago, ILMarch 31– April 4, 2012
   Google Scholar
• SandlerASchillerJHHirshVA phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC)ASCO Meeting Abstracts201129Suppl 15TPS217
   Google Scholar
• ScagliottiGVNovelloSSchillerJHRationale and design of MARQUEE: A Phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancerClin Lung Cancer201213539139522440336
   PubMed Web of Science ®Google Scholar
• FasoloASessaCGianniLBrogginiMSeminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologistAnn Oncol2013241142023110808
   PubMed Web of Science ®Google Scholar
• PelosiGGaspariniPCavazzaAMultiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) geneLung Cancer201277350751422705117
   PubMed Web of Science ®Google Scholar